Poseida Therapeutics price target raised to $10 from $8 at Piper Sandler

Piper Sandler raised the firm’s price target on Poseida Therapeutics (PSTX) to $10 from $8 and keeps an Overweight rating on the shares. At ASH, early Phase I r/rMM data on 2.0M P-BCMA-ALLO1 cells/kg showed an impressive 82% ORR, the firm says. Piper anticipates Poseida and Roche (RHHBY) will continue to optimize dose/preconditioning, and present P-BCMA-ALLO1 durability data in 2024. Roche will initiate a Phase I study of P-CD19CD20-ALLO1 in r/r B-cell lymphoma patients in early 2024. Poseida will report Phase I PMUC1C-ALLO1 solid tumor data in the first half of 2024.